NASDAQ · NBP
Healthcare · Biotechnology
$1.40
Up+$0.04 (+2.94%)
Updated Oct 7, 2026, 5:58 AM
SID Score
3.1/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · NBP
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
NBP closed at $1.40 after 21 trading sessions, down 21.35% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $1.38 | $1.44 | $1.38 | $1.40 | 379.84K |
| Oct 5, 2026 | $1.37 | $1.385 | $1.35 | $1.36 | 184.99K |
| Oct 2, 2026 | $1.34 | $1.36 | $1.33 | $1.355 | 252.91K |
| Oct 1, 2026 | $1.36 | $1.39 | $1.31 | $1.34 | 342.37K |
| Sep 30, 2026 | $1.38 | $1.40 | $1.35 | $1.365 | 250.3K |
| Sep 29, 2026 | $1.38 | $1.41 | $1.35 | $1.37 | 294.57K |
| Sep 28, 2026 | $1.38 | $1.39 | $1.345 | $1.36 | 375.31K |
| Sep 25, 2026 | $1.43 | $1.44 | $1.315 | $1.38 | 6.61M |
| Sep 24, 2026 | $1.52 | $1.54 | $1.425 | $1.45 | 831.82K |
| Sep 23, 2026 | $1.58 | $1.59 | $1.505 | $1.53 | 593.31K |
| Sep 22, 2026 | $1.61 | $1.615 | $1.54 | $1.59 | 464.89K |
| Sep 21, 2026 | $1.63 | $1.64 | $1.61 | $1.61 | 243.6K |
| Sep 18, 2026 | $1.62 | $1.65 | $1.60 | $1.60 | 197.63K |
| Sep 17, 2026 | $1.59 | $1.64 | $1.59 | $1.63 | 180.39K |
| Sep 16, 2026 | $1.59 | $1.60 | $1.565 | $1.57 | 328.95K |
| Sep 15, 2026 | $1.60 | $1.618 | $1.57 | $1.59 | 279.51K |
| Sep 14, 2026 | $1.59 | $1.63 | $1.59 | $1.61 | 206.58K |
| Sep 11, 2026 | $1.70 | $1.71 | $1.58 | $1.59 | 252.83K |
| Sep 10, 2026 | $1.67 | $1.70 | $1.6595 | $1.69 | 129.33K |
| Sep 9, 2026 | $1.77 | $1.80 | $1.68 | $1.70 | 309.33K |
| Sep 8, 2026 | $1.79 | $1.825 | $1.75 | $1.78 | 127.01K |
The latest Smart Investors Daily articles mentioning NBP.
Company
Market Activity
Research & News
NBP research
Company profile and research snapshot.
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. It integrates scientific discovery with strategic planning and project management to move therapies from research toward potential patient use. Its pipeline includes Givastomig, VIS-101, Ragistomig and Uliledlimab.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 20, 2026 | HC Wainwright & Co. | Buy | — |
| Apr 8, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 16, 2026 | HC Wainwright & Co. | Buy | — |
| Feb 6, 2026 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Sep 18, 2026
NovaBridge Biosciences (NASDAQ:NBP) held its quarterly earnings conference call on Thursday. Below is the complete transcript from the call. This content is powered by Benzinga APIs. For comprehensive financial data and
Yahoo · Aug 27, 2026
ROCKVILLE, Md., Aug. 27, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a global biotechnology company that identifies differentiated innovation and applies disciplined development, financing, and partnering strategies to create value, today announced that the Company’s leadership will participate in the following investor conferences in September 2026: Conference details: Cantor 2026 Global Healthcare ConferenceFormat: Fireside Chat and one-on-one
Benzinga · Jun 16, 2026
Registrational Phase 3 Trial Expected to Begin as Early as Q4 2026Detailed Phase 1b Data Expected to be Presented at a Major Medical Conference in H2 2026ROCKVILLE, Md., June 16, 2026 (GLOBE NEWSWIRE) -- NovaBridge
Yahoo · Feb 19, 2026
Appointment is a positive endorsement of NovaBridge’s unique hub-and-spoke model and focus on creating shareholder value by accelerating the development of transformative medicines for patients around the worldAs a physician-entrepreneur and founder with a proven track record in business development, Dr. Cunningham aims to bolster NovaBridge’s mission to accelerate access to transformative medicinesDr. Cunningham, co-founder of NovaBridge subsidiary company Visara, Inc., will also join the Board
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning NBP.
